ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1290

Am80, a Synthetic Retinoic Acid Receptor α-Specific Agonist, Suppresses Peritoneal Fibrosis via Inhibition of Krüppel-Like Transcription Factor 5 in Mice

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis


  • Muta, Kumiko, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
  • Nakazawa, Yuka, Hokusyo Central Hospital, Nagasaki, Japan
  • Obata, Yoko, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
  • Inoue, Hiro, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
  • Torigoe, Kenta, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
  • Yamamoto, Kazuo, Nagasaki University School of Medicine, Nagasaki, Japan
  • Nishino, Tomoya, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan

We presented previously that Am80, a synthetic retinoic acid receptor a specific agonist, inhibited the expression of Krüppel-like transcription factor 5 (KLF5) and reduced peritoneal fibrosis in mice. Now, we examined further detail about the mechanism to inhibit peritoneal fibrosis.


Peritoneal fibrosis was induced by intraperitoneal injection of chlorhexidine gluconate (CG) into peritoneal cavity of ICR mice. Am80 was administered orally for every day from the start of CG injection. After 3 weeks of treatment, peritoneal tissues were examined using serial sections by immunohistochemistry to identify what kind of cells expressed KLF5. Am80 was given in mouse fibroblasts stimulated by transforming growth factor β1 (TGF-β1) and the expression of KLF5 was assessed by Western blotting.


While KLF5 was expressed in the thickened submesothelial area of CG injected mice, Am80 treatment reduced KLF5 expression and remarkably attenuated peritoneal thickening. The numbers of TGFβ positive cells, a-smooth muscle actin (aSMA) or F4/80 positive cells were significantly decreased in Am80 treated group. KLF5 was expressed in aSMA, F4/80 or CD31 positive cells. Western blotting for KLF5 showed the tendency that KLF5 expression was decreased in higher concentration of Am80 in mouse fibroblasts stimulated by TGF-β1 in vitro.


These results indicate the KLF5 might not only associate phenotypical differentiation from fibroblasts to myofibroblasts but also regulate inflammatory responses and angiogenesis in peritoneal fibrosis model. Am80 can suppress peritoneal fibrosis through inhibiting these mechanisms.